Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;67(1):122-31.
doi: 10.1002/ana.21843.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

John C Morris  1 , Catherine M Roe, Chengjie Xiong, Anne M Fagan, Alison M Goate, David M Holtzman, Mark A Mintun
Affiliations

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

John C Morris et al. Ann Neurol. 2010 Jan.

Abstract

Objective: To examine interactions of apolipoprotein E (APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging.

Methods: Two hundred forty-one cognitively normal individuals, aged 45-88 years, had cerebral amyloid imaging studies with Pittsburgh Compound-B (PIB). Of the 241 individuals, 168 (70%) also had cerebrospinal fluid (CSF) assays of amyloid-beta(42) (Abeta(42)), tau, and phosphorylated tau (ptau(181)). All individuals were genotyped for APOE.

Results: The frequency of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age-dependent manner from 0% at ages 45-49 years to 30.3% at 80-88 years. Reduced levels of CSF Abeta(42) appeared to begin earlier (18.2% of those aged 45-49 years) and increase with age in higher frequencies (50% at age 80-88 years) than elevations of MCBP. There was a gene dose effect for the APOE4 genotype, with greater MCBP increases and greater reductions in CSF Abeta(42) with increased numbers of APOE4 alleles. Individuals with an APOE2 allele had no increase in MCBP with age and had higher CSF Abeta(42) levels than individuals without an APOE2 allele. There was no APOE4 or APOE2 effect on CSF tau or ptau(181).

Interpretation: Increasing cerebral Abeta deposition with age is the pathobiological phenotype of APOE4. The biomarker sequence that detects Abeta deposition may first be lowered CSF Abeta(42), followed by elevated MCBP for PIB. A substantial proportion of cognitively normal individuals have presumptive preclinical AD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean cortical binding potentials for Pittsburgh Compound-B (PIB) in 241 cognitively normal participants as a function of age at clinical assessment and of (A.) the presence (red squares) or absence (black squares) of the ε4 allele of Apolipoprotein E (APOE) or (B.) the presence (green squares) or absence (black squares) of the ε2 allele of APOE.
Figure 1
Figure 1
Mean cortical binding potentials for Pittsburgh Compound-B (PIB) in 241 cognitively normal participants as a function of age at clinical assessment and of (A.) the presence (red squares) or absence (black squares) of the ε4 allele of Apolipoprotein E (APOE) or (B.) the presence (green squares) or absence (black squares) of the ε2 allele of APOE.
Figure 2
Figure 2
Unadjusted associations with age at clinical assessment and the presence (red squares) or absence (black squares) of APOE4 in 168 cognitively normal participants for cerebrospinal fluid (CSF) measures of: A. amyloid-beta42 (Aβ42); B. tau; and C. tau phosphorylated at the threonine 181 position (ptau181).
Figure 2
Figure 2
Unadjusted associations with age at clinical assessment and the presence (red squares) or absence (black squares) of APOE4 in 168 cognitively normal participants for cerebrospinal fluid (CSF) measures of: A. amyloid-beta42 (Aβ42); B. tau; and C. tau phosphorylated at the threonine 181 position (ptau181).
Figure 2
Figure 2
Unadjusted associations with age at clinical assessment and the presence (red squares) or absence (black squares) of APOE4 in 168 cognitively normal participants for cerebrospinal fluid (CSF) measures of: A. amyloid-beta42 (Aβ42); B. tau; and C. tau phosphorylated at the threonine 181 position (ptau181).
Figure 3
Figure 3
Unadjusted associations with age at clinical assessment and the presence (green squares) or absence (black squares) of APOE2 in the CSF of 168 cognitively normal individuals for CSF measures of A. Aβ42; B. tau; and C. ptau181.
Figure 3
Figure 3
Unadjusted associations with age at clinical assessment and the presence (green squares) or absence (black squares) of APOE2 in the CSF of 168 cognitively normal individuals for CSF measures of A. Aβ42; B. tau; and C. ptau181.
Figure 3
Figure 3
Unadjusted associations with age at clinical assessment and the presence (green squares) or absence (black squares) of APOE2 in the CSF of 168 cognitively normal individuals for CSF measures of A. Aβ42; B. tau; and C. ptau181.
Figure 4
Figure 4
A. Frequency by age group for individuals with MCBP for PIB >0.18 (“PIB-positive”) in 241 cognitively normal individuals as a function of the presence (red bars) or absence (black bars) of APOE4. B. Frequency by age group for individuals with CSF Aβ42 <500pg/mL (“CSF Aβ42 positive”) in 168 cognitively normal individuals as a function of the presence (red bars) or absence (black bars) of APOE4.
Figure 4
Figure 4
A. Frequency by age group for individuals with MCBP for PIB >0.18 (“PIB-positive”) in 241 cognitively normal individuals as a function of the presence (red bars) or absence (black bars) of APOE4. B. Frequency by age group for individuals with CSF Aβ42 <500pg/mL (“CSF Aβ42 positive”) in 168 cognitively normal individuals as a function of the presence (red bars) or absence (black bars) of APOE4.
See this image and copyright information in PMC

References

    1. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer’s disease. J Mol Neurosci. 2001;17:101–118. - PubMed
    1. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23:138–144. - PubMed
    1. Troncoso JC, Cataldo M, Nixon RA, et al. Neuropathology of preclinical and clinical late-onset Alzheimer’s disease. Ann Neurol. 1998;43:673–676. - PubMed
    1. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in “normal” aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168–1174. - PubMed
    1. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45:358–368. - PubMed

Publication types

MeSH terms